摘要
目的评估替罗非班用于急性ST段抬高型心肌梗死(STEMl)患者急诊经皮冠状动脉介入治疗(PCI)时的安全性及有效性。方法已确诊的STEMI患者PCI术前随机分为试验组和对照组,试验组PCI术前静脉使用盐酸替罗非班。观察2组患者PCI术前、术后前向血流(TIMI)血流情况、术后1周左心室射血分数、出血并发症和30 d内发生心血管事件。结果与PCI组相比,替罗非班组PCI术后TIMIⅢ级血流获得率较PCI组高,差异有统计学意义(P<0.05);术后1周左室射血分数高于PCI组,差异有统计学意义(P<0.05),出血并发症发生率有高于PCI组趋势,但差异无统计学意义(P>0.05),无严重出血。30 d内的主要心血管事件发生率低于PCI组,差异有统计学意义(P<0.05)。结论替罗非班可改善STEMI患者梗死相关血管的TIMI血流,可安全用于STEMI的急诊介入治疗中,明显减少急性心肌梗死患者30 d内心血管事件的发生率。
[ Objective] To evaluate the safety and effectiveness of the tirofiban, which was used in the percutaneous coronary intervention therapy for the patients with acute myocardial infarction with st-segment elevation （STEMI）. [ Methods] The patients with confirmed STEMI were randomly divided into test group and control group, and the test group received intravenous tirofiban before PCI. The TIMI blood flow before and after PCI, the left ventricular ejection fraction after PCI for 1 week, bleeding complications and the cardiovascular events which occurred in 30 days were observed in both 2 groups. [ Results] Compared with the PCI group, the tirofiban group had the higher harvest rate of TIMI Class m blood flow, and the difference was significant（ P 〈0.05） ; the left ventricular ejection fraction after PCI for 1 week was higher than the PCI group, and the difference was significant（ P 〈0.05 ） ; bleeding complications had the tendency of being higher than the PCI group, but the difference was not significant （ P 〉 0. 05 ）, with no sever hemorrhage ; the incidence of the main cardiovascular events was lower than the PCI group, and the differences was significant （P 〈 0.05）. [ Conclusion ] The tirofiban can improve the TIMI blood flow in the infarct related artery of patients with STEMI, so it can be safely used in the emergency interventional treatment of STEMI, and significantly lower the incidence of the cardiovascular events which occur in 30 days.
出处
《职业与健康》
CAS
2009年第7期780-781,共2页
Occupation and Health
关键词
盐酸替罗非班
心肌梗死
介入治疗
Tirofiban hydroehloride
Myocardial infarction
Interventional treatment
